Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the appointment of Maya Martinez-Davis (46), as Global Head of Oncology Franchise for its biopharma business. She will report to Rehan Verjee, Chief Marketing and Strategy Officer of the Healthcare business sector of Merck KGaA, Darmstadt, Germany, and will be based in Billerica, Massachusetts, USA. Martinez-Davis’ appointment is effective as of today.
In her new role leading the Global Oncology Franchise, Martinez-Davis’ responsibilities will include defining integrated global oncology strategies, and delivery of therapeutic launches, starting with Avelumab*, an investigational anti-PD-L1 antibody initially discovered and developed by Merck KGaA, Darmstadt, Germany, and currently managed under a strategic alliance with Pfizer. The first potential commercial launch for Avelumab is expected in 2017.
“Maya’s considerable experience in oncology, which includes the recent successful launch of Ibrance? ** in the USA, make her a valued addition to our team as we endeavor to bring new therapeutic options to patients living with cancer,” said Rehan Verjee. “This is a very exciting time for our company as we advance our promising oncology and immuno-oncology pipeline and attract leading industry talent to our company.”
Prior to joining Merck KGaA, Darmstadt, Germany, Martinez-Davis was a senior executive with Pfizer for more than a decade, delivering on therapeutic area portfolio strategies, in-market growth strategies, and major launches. Prior to her tenure with Pfizer, she held senior-level and director-level positions with Aventis Pharma in oncology.
Martinez-Davis assumes the role of her predecessor, Andrew Schiermeier.
* Avelumab is the proposed International Non-proprietary Name for the anti-PD-L1 monoclonal antibody (MSB0010718C). Avelumab is under clinical investigation and has not been proven to be safe and effective. There is no guarantee any product will be approved in the sought-after indication by any health authority worldwide.
** Ibrance? is a registered trademark of Pfizer